Skip to content
ClinCalc Pro
Menu
Calculators Drugs Pathways AI Dx Donate Get the App
Atypical (Second-generation) Antipsychotic — Dopamine D3/D2 Partial Agonist

Cariprazine

Brand names: Reagila

Cariprazine is a second-generation antipsychotic used for the treatment of schizophrenia.

Dosing — being independently re-sourced

ClinCalc Pro is rebuilding its dose data from primary open sources — the manufacturer SmPC (eMC), the WHO Model Formulary and other official references — under clinician review. This drug's structured dose is not yet published here. Confirm all doses against the product SmPC and your local formulary before prescribing.

Clinical monograph

How it works

It is a partial agonist at dopamine D3 and D2 receptors and at serotonin 5-HT1A receptors, with antagonism at 5-HT2B and 5-HT2A receptors.

Prescribing in practice

  • Owing to its long-acting active metabolites, effects and side effects can persist for weeks after stopping, so changes should be made gradually with monitoring.
  • Akathisia and extrapyramidal symptoms are common, and impulse-control disorders have been reported with dopamine partial agonists.
  • Avoid in dementia-related psychosis in the elderly and adjust for strong CYP3A4 interactions; avoid in severe hepatic or renal impairment.

Monitoring

Monitor for akathisia and extrapyramidal symptoms, weight, glucose, lipids and mental state.

Counselling the patient

  • Because the drug stays in the body for some time, side effects may appear or persist after a dose change.
  • Report restlessness, abnormal movements or new compulsive behaviours.
  • It may take several weeks to feel the full benefit.

Evidence & guidelines

Randomised controlled trials support cariprazine's efficacy in schizophrenia, including predominant negative symptoms.

Reference: NICE TA810 (Cariprazine for Schizophrenia); Reagila SPC; Drug verified in RxNorm (NLM); confirm dosing against the manufacturer SPC (eMC). Verify against your local formulary and current prescribing references before prescribing. Monograph status: clinician-reviewed (2026-07-04).

Related

Curated clinical cross-links plus same-class fallbacks.

Calculators
Pathways